Moleculin Biotech, Inc. (MBRX)

NASDAQ: MBRX · Real-Time Price · USD
0.3122
-0.0098 (-3.04%)
At close: Jun 27, 2025, 4:00 PM
0.3000
-0.0122 (-3.91%)
After-hours: Jun 27, 2025, 7:59 PM EDT
-3.04%
Market Cap 4.41M
Revenue (ttm) n/a
Net Income (ttm) -23.23M
Shares Out 14.13M
EPS (ttm) -4.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,263,094
Open 0.3050
Previous Close 0.3220
Day's Range 0.2950 - 0.3240
52-Week Range 0.2500 - 4.7070
Beta 1.56
Analysts Strong Buy
Price Target 5.33 (+1,607.24%)
Earnings Date Aug 13, 2025

About MBRX

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 2, 2016
Employees 17
Stock Exchange NASDAQ
Ticker Symbol MBRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price forecast is $5.33, which is an increase of 1,607.24% from the latest price.

Price Target
$5.33
(1,607.24% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CPRX
1 day ago - Benzinga

Moleculin Announces $5.9 Million Public Offering

HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeti...

7 days ago - GlobeNewsWire

Moleculin Participates in Virtual Investor “What This Means” Segment

Watch the “What This Means" segment here

10 days ago - GlobeNewsWire

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer  FDA recommends inclusion of patients as young as 6 months – younger than ...

10 days ago - GlobeNewsWire

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad po...

23 days ago - GlobeNewsWire

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Annamycin delivering better performance 7 th line than would be expected even in 2 nd line for monotherapy

23 days ago - GlobeNewsWire

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Walter Klemp - Founder, President, CEO and Chairm...

6 weeks ago - Seeking Alpha

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML

6 weeks ago - GlobeNewsWire

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested

6 weeks ago - GlobeNewsWire

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targetin...

7 weeks ago - GlobeNewsWire

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing pivotal, adaptive Phase 3 clinical trial (the “MIRACLE...

7 weeks ago - GlobeNewsWire

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Company continues to expand global IP coverage and claims to major markets, now extending to June 2040  HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” o...

7 weeks ago - GlobeNewsWire

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistica...

2 months ago - GlobeNewsWire

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates target...

2 months ago - GlobeNewsWire

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical ...

3 months ago - GlobeNewsWire

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO John Paul Waymack - Senior CMO Jonathan Foster - ...

3 months ago - Seeking Alpha

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025

3 months ago - GlobeNewsWire

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates target...

3 months ago - GlobeNewsWire

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

On-demand video webcast now available here HOUSTON , March 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a br...

3 months ago - PRNewsWire

Moleculin to Present at the 37th Annual ROTH Conference

Live webcast fireside chat on Tuesday, March 18 th at 11:00 AM PT HOUSTON , March 10, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmace...

3 months ago - PRNewsWire

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

New patents will extend coverage to major markets outside the U.S., expanding upon existing U.S. claims Affirms expectations for an initial data readout of the phase 3 MIRACLE trial for the second hal...

4 months ago - PRNewsWire

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

HOUSTON , March 3, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting ...

4 months ago - PRNewsWire

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

HOUSTON , Feb. 25, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting ...

4 months ago - PRNewsWire

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

On Thursday, Moleculin Biotech, Inc., MBRX stock is surging with a strong session volume of 64.85 million compared to an average volume of 157.048K, as per data from Benzinga Pro.

4 months ago - Benzinga

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

HOUSTON , Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting ...

4 months ago - PRNewsWire